Immunovant (IMVT) Research & Development (2018 - 2026)

Immunovant's Research & Development history runs 9 years deep, the most recent figure standing at $142.3 million for Q1 2026.

• Quarterly Research & Development rose 51.93% year-over-year to $142.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $456.7 million (up 26.53% YoY) and the FY2026 annual result came in at $456.7 million, up 26.53% from the prior year.
• Research & Development was $142.3 million for Q1 2026 at Immunovant, up from $98.9 million in the prior quarter.
• Across five years, Research & Development topped out at $142.3 million in Q1 2026 and bottomed at $28.4 million in Q2 2022.
• A 5-year average of $71.9 million and a median of $66.1 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development soared 102.82% — and 2025, when it advanced 4.66%.
• Immunovant's Research & Development stood at $42.3 million in 2022, then gained by 14.4% to $48.3 million in 2023, then surged by 95.54% to $94.5 million in 2024, then climbed by 4.66% to $98.9 million in 2025, then soared by 43.83% to $142.3 million in 2026.
• Business Quant data shows IMVT's Research & Development at $142.3 million in Q1 2026, $98.9 million in Q4 2025, and $114.2 million in Q3 2025.